Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC